Associations of cholesteryl ester transfer protein (CETP) gene variants with pituitary adenoma

Sidaraitė, Agnė; Liutkevičienė, Rasa; Glebauskiene, Brigita; Vilkeviciute, Alvita; Kriauciuniene, Loresa

doi:10.5507/bp.2019.016

Cited by 8 publications

(6 citation statements)

References 55 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…CETP is highly expressed in many cancers, such as colorectal, gastric, breast, pituitary adenoma and gallbladder cancers. 8,[22][23][24][25] Recent studies on the significance of CETP in breast cancer development have confirmed that CETP can help improve the survival outcomes of breast cancer cells as well as promote resistance to apoptosis. Furthermore, Mihajlovic et al indicated that CETP activity increased during tumor progression in CRC.…”

Section: Discussionmentioning

confidence: 99%

Evacetrapib Elicits Antitumor Effects on Colorectal Cancer by Inhibiting the Wnt/β-Catenin Signaling Pathway and Activating the JNK Signaling Pathway

Dong

et al. 2022

Biological & Pharmaceutical Bulletin

View full text Add to dashboard Cite

Despite advances in colorectal cancer (CRC) treatment, most advanced CRC patients who experience disease progression after chemotherapy, targeted therapy, and immunotherapy face a situation in which there is no available medicine. Thus, new therapeutic drugs for CRC are urgently needed. Studies have shown that cholesteryl ester transfer protein (CETP) has a vital role in tumor development and is a possible target for CRC therapy. We found that Evacetrapib, a CETP inhibitor, suppressed CRC cell growth by inhibiting the Wnt/β-catenin signaling pathway and activating the c-Jun NH2-terminal kinase (JNK) signaling pathway in CRC. Therefore, Evacetrapib displays an anti-cancer effect and is a possible option for treating CRC.

show abstract

Section: Discussionmentioning

confidence: 99%

Evacetrapib Elicits Antitumor Effects on Colorectal Cancer by Inhibiting the Wnt/β-Catenin Signaling Pathway and Activating the JNK Signaling Pathway

Dong

et al. 2022

Biological & Pharmaceutical Bulletin

View full text Add to dashboard Cite

show abstract

“…Based on the histopathological view group was divided into invasive and non-invasive; based on hormone levels in blood serum, two groups were created: active and inactive PA. Relapse was diagnosed if the enlargement of a residual tumor or a new growth was noticed and documented on follow-up MRI. PA’s hormonal activity, recurrence [ 18 ] and invasiveness [ 19 ] were previously briefly described.…”

Section: Methodsmentioning

confidence: 99%

Molecular Markers of Telomerase Complex for Patients with Pituitary Adenoma

et al. 2022

Self Cite

View full text Add to dashboard Cite

Pituitary adenoma (PA) is the most common benign tumor of the pituitary gland. The pathogenesis of most PA is considered as a multifactorial process, that involves genetic mutations, alterations in gene transcription, and epigenetic factors. Their interaction promotes tumorigenesis. The processes are increasingly focused on changes in telomere length. Our study enrolled 126 patients with PA and 368 healthy subjects. DNA samples from peripheral blood leukocytes were purified by the DNA salting-out method. The RT-PCR carried out SNPs and relative leukocyte telomere lengths (RLTL). ELISA determined the level of TEP1 in blood serum. Binary logistic regression revealed that TERC rs35073794 is likely associated with increased odds of PA development and macro-PA development. It is also associated with decreased odds of active PA, non-invasive PA, and PA without relapse development. Also, we discovered that PA patients with at least one G allele of the TEP1 gene polymorphism rs1713418 have lower serum TEP1 levels than healthy individuals (p = 0.035). To conclude, the study revealed that TERC rs35073794 might be a potential biomarker for PA development.

show abstract

“…Based on our inclusion and exclusion criteria (27), two groups were formed in our study: PA group (n=141) and controls (n=287) ( Figure 1).…”

Section: Methodsmentioning

confidence: 99%

“…DNA extraction and genotyping. The evaluation of PA hormonal activity, invasiveness and recurrence has been described in detail previously (27). DNA extraction and genotyping were based on a real-time polymerase chain reaction (RT-PCR) method (28).…”

Section: Evaluation Of Pas' Hormonal Activity Invasiveness Recurrenmentioning

confidence: 99%

Do TRIB1 and IL-9 Gene Polymorphisms Impact the Development and Manifestation of Pituitary Adenoma?

Mickevičius

Vilkeviciute

Glebauskiene

et al. 2020

In Vivo

Self Cite

View full text Add to dashboard Cite

Background/Aim: To evaluate the association between TRIB1(rs6987702) and IL-9(rs1859430, rs2069870) genotypes with the development and manifestation of pituitary adenoma (PA). Materials and Methods: The study group included 141 patients with PA and the control group consisted of 287 healthy people. The genotyping of rs6987702, rs1859430 and rs2069870 was carried out using a real-time polymerase chain reaction. Results: Statistically significant results were obtained regarding the rs1859430, but there were no significant results regarding rs6987702. We found that the rs1859430 A/A genotype increased the odds of having recurrent PA six times (p=0.006) under the co-dominant model and four times (p=0.021) under the recessive model. Furthermore, the analysis showed that the G/A genotype increased the odds of having recurrent PA 2.3 times (p=0.003) under the co-dominant model, while G/A and A/A genotypes increased the odds 2.7 times (p=0.011) under the over-dominant model. Conclusion: Certain genotypes of rs1859430 can be associated with PA recurrence. Pituitary adenoma (PA) is a benign pituitary gland tumor, which starts from the cells of adenohypophysis (1). PAs are mainly inactive, but certain types of PAs secrete hormones and become clinically apparent (2). They can also be classified according to their size: microadenomas, which are more commonly found in female and <60 years old patients, and macroadenomas, which are more prevalent in male and >60 years old patients (3-5). According to the latest statistical report of Central Brain Tumor Registry of the United States (CBTRUS), the incidence rate of benign pituitary tumors has increased, and currently they present 16.4% of all primary brain and central nervous system tumors (6). The report of Brain Tumor Register of Japan published in 2017 showed that pituitary gland was a primary location for 22.6% of all brain tumors and 91.1% of them were benign (7). Meta-analysis of 143 studies showed that the recurrence rate depends on the type of PA (8) and varies from 5% to 16% (7). Although the exact mechanism of PA development is still unknown, it may include various immunogenetic factors. Many potential molecular markers, which might be involved in the tumorigenesis of PAs, are currently under investigation. In the present study, one TRIB1 gene polymorphism and two IL-9 gene polymorphisms were selected for further investigation. Tribbles-1 (TRIB1) is a protein, encoded by the TRIB1 gene, most commonly found in the nucleus of a cell. This protein belongs to a group of pseudokinases, which consist of 3 different domains: N-terminal PEST domain, pseudokinase domain and C-terminal COP1 binding peptide domain. TRIB kinases have unique sequences located at the C-terminal end (9). Tribbles-1 is mostly found in myeloid cells. It is thought to be important in intracellular signaling, and thereby, to participate in the management of cell cycle, differentiation, metabolism and proliferation, migration and invasion (9-11). TRIB1 is thought to have oncogenic properties. Miyajima et a...

show abstract

Associations of cholesteryl ester transfer protein (CETP) gene variants with pituitary adenoma

Cited by 8 publications

References 55 publications

Evacetrapib Elicits Antitumor Effects on Colorectal Cancer by Inhibiting the Wnt/β-Catenin Signaling Pathway and Activating the JNK Signaling Pathway

Evacetrapib Elicits Antitumor Effects on Colorectal Cancer by Inhibiting the Wnt/β-Catenin Signaling Pathway and Activating the JNK Signaling Pathway

Molecular Markers of Telomerase Complex for Patients with Pituitary Adenoma

Do TRIB1 and IL-9 Gene Polymorphisms Impact the Development and Manifestation of Pituitary Adenoma?

Contact Info

Product

Resources

About